Overview

New criteria for classifying and diagnosing hyperglycaemia first detected during pregnancy have been accepted by a group of experts convened by WHO. These new criteria are an update of recommendations published by WHO in 1999.

Contents

• Executive summary
• 1. Introduction
  • 1.1 Objectives and target audience
  • 1.2 Members of the Guideline Development Group
  • 1.3 Funding and declarations of interest
  • 1.4 Methodology and process
  • 1.5 Adaptation and implementation
  • 1.6 Update
  • 1.7 Format and dissemination
  • 1.8 Impact and quality of the guideline
• 2. Background
  • 2.1 History of diagnostic criteria for Gestational Diabetes Mellitus (GDM)
  • 2.2 Most commonly used diagnostic criteria for GDM
  • 2.3 The need to update the 1999 WHO criteria
• 3. Questions addressed in systematic reviews to inform guideline development
  • 3.1 Is the association between gestational diabetes and adverse pregnancy outcomes, independent of other risk factors such as age, body mass index and weight gain during pregnancy?
  • 3.2 What is the increased risk of adverse pregnancy outcomes conferred by a diagnosis of gestational diabetes defined by a 75g OGTT?
  • 3.3 Can treatment for gestational diabetes reduce adverse pregnancy outcomes?
  • 3.4 What is the population impact of using the WHO 1999 and IADPSG diagnostic criteria for GDM if applied to all asymptomatic pregnant women followed by treatment for those identified with GDM?
• 4. Recommendations
  • 4.1 Classification of hyperglycaemia first detected during pregnancy
  • 4.2 Diagnosis of diabetes mellitus in pregnancy
  • 4.3 Diagnosis of gestational diabetes mellitus
• 5. Implications and recommendations for future research
• References
• Annex 1 Importance of outcomes for the assessment of GDM treatment effects (GRADE method)
• Annex 2 Summary Tables

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.